U.S. markets closed

Humanigen, Inc. (HGEN)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
18.59+0.57 (+3.16%)
At close: 4:00PM EST
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bearishpattern detected
Commodity Channel Index

Commodity Channel Index

Previous Close18.02
Open18.50
Bid18.90 x 800
Ask19.09 x 900
Day's Range18.04 - 19.61
52 Week Range1.65 - 33.95
Volume729,897
Avg. Volume936,908
Market Cap1.022B
Beta (5Y Monthly)-1.41
PE Ratio (TTM)N/A
EPS (TTM)-2.00
Earnings DateNov 11, 2020
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est29.33
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Overvalued
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
View more
  • Business Wire

    Humanigen to Present at Multiple Investor Conferences in March

    Humanigen, Inc. (Nasdaq: HGEN) ("Humanigen"), a clinical stage biopharmaceutical company focused on preventing and treating an immune hyper-response called ‘cytokine storm’ with its lead drug candidate, lenzilumab™, today announced that the Company’s management team will present and host meetings with investors at the H.C. Wainwright Global Life Sciences Conference being held from March 9-10, 2021, the Roth Conference being held from March 15-17, 2021, and the Oppenheimer Annual Healthcare Conference being held from March 16-17, 2021.

  • Business Wire

    Humanigen to Present and Participate at Multiple Upcoming Investor and Industry Conferences

    Humanigen, Inc. (Nasdaq: HGEN) ("Humanigen"), a clinical stage biopharmaceutical company focused on preventing and treating an immune hyper-response called ‘cytokine storm’ with its lead drug candidate, lenzilumab™, today announced that the Company’s CEO, Cameron Durrant, will participate, present and host meetings with investors and industry colleagues at the BIO CEO & Investor Virtual Conference and the Endpoints Webinars panel, "Repurposing drugs for new indications: benefits and challenges," and will co-host the Vanguard Network Life Sciences Quarterly Forum. Management will also participate in a Fireside Chat with Cantor Fitzgerald Analyst Louise Chen on February 26, 2021.

  • Humanigen Elects Dr. Dale Chappell to Board of Directors
    Business Wire

    Humanigen Elects Dr. Dale Chappell to Board of Directors

    Humanigen announces the election of Dr. Dale Chappell, the Company's chief scientific officer, to serve as a board director of the Company.